Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

Biomedicine and Pharmacotherapy

Volumn 55, Issue 1, 2001, Pages 7-15

  Pomerantz, R J ^a,b  

^a Department of Medicine   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

HAART; HIV 1; Residual replication

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; RNA;

BRAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MONOCYTE; PERSISTENT INFECTION; PLASMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TESTIS; VIRUS REPLICATION;

EID: 0035113144     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)00016-0     Document Type: Article

References (79)

1. AIDS and other diseases due to HIV infection
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
3. Prognosis in HIV infection predicted by the quantity of virus in plasma
4. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. A controlled trial of two nucleoside analogous plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. HIV-1 in the semen of men receiving highly active anti-retroviral therapy
9. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
10. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
11. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy
12. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy
13. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
14. Induction of HIV-1 replication in latently infected CD4+ T-cells using a combination of cytokines
15. Analysis of the evolution of HIV-1 pol sequences in latent HIV-1 present in resting CD4+ T-lymphocytes in HIV-1-infected children treated with HAART
16. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection
17. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection
18. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent anti-retroviral therapy
19. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals
20. HIV-1 shedding pattern in semen correlates with the compartmentalization of viral quasispecies between blood and semen
21. Sites of productive infection of HIV in the male GU tract
22. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
23. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
24. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged depression of plasma viremia
25. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
26. Reverse transcription takes place within extracellular HIV-1 virions: Potential biological significance
27. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: Direct assessment of resistance to reverse transcriptase inhibitors in vivo
28. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: An important stage for viral infection of nondividing cells
29. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART)
30. HIV-1 replication in patients with undetectable plasma virus receiving HAART
31. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/mL
32. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
33. Antiretroviral drugs and the central nervous system
34. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
35. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy
36. Biphasic decay of latent HIV-1 in resting CD4+ T cells in acute seroconverters
37. Effect of interleukin-2 on the pool of latently infected resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
38. Immuno-activation with anti-CD3 and recombinant human IL-2 and HIV-1-infected patients on potent antiretroviral therapy
39. Re-emergence of HIV afer stopping therapy
40. Influence of interleukin-2 (IL-2) on productive and latent HIV-1 infection and on viral rebound
41. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
42. Aggressive HAART + IL-2 is unable to induce HIV remission in early-stage disease after 18 months
43. Induction and elimination of latent HIV via T-cell activation
44. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
45. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. : F
46. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication
47. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
48. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleotide triphosphate pools
49. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
50. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide
51. Viral load rebound upon discontinuation of d4T + ddI and NVP with or without hydroxyurea (HU) during primary HIV infection (PHI)
52. The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line
53. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors
54. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
55. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection results of the ANRS 053 Trial
56. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity
57. Long-term effects of antiretroviral combination therapy on HIV type I DNA levels
58. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia
59. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients
60. Comparison of cell-associated HIV-1 DNA and RNA in triple-drug-treated versus untreated persons with primary HIV-1: Evidence for persistent viral reservoirs
61. Treatment of HIV infection with cytoreductive agents
62. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART
63. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
64. Levels of human immunodeficiency virus type 1 specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
65. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia
66. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia
67. Plasma viral loads approximate pre-HAART levels after discontinuation of HAART
68. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure
69. Structured cyclic antiretroviral therapy interruption (STI) in chronic infection may induce immune responses against HIV-1 antigen associated with spontaneous drop in viral load
70. Significant delay in plasma vRNA rebound during a scheduled treatment interruption in HIV-1 chronically infected patients previously on effective therapy
71. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
72. Structured treatment interruption in chronically HIV-1-infected patients after long-term viral suppression
73. Increase in breadth and frequency of CTL responses following structured therapy interruptions in individuals treated with HAART during acute HIV-1 infection
74. Intermittent interruptions of antiretroviral therapy in chronically HIV-1 infected patients do not induce immune control of HIV
75. Rapid activation of lymph nodes upon interrupting HAART in HIV-infected patients following prolonged viral suppression
76. Control of viremia after treatment interruption
77. No detectable HIV RNA in thirteen individuals months after stopping antiretroviral therapy
78. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
79. Residual HIV-1 disease in the era of highly active antiretroviral therapy